Mounjaro®
Starting from £179.99/mo
Start journey Learn moreCurrent UK guidance is clear: stop Wegovy at least two months before trying to conceive. That two-month window allows semaglutide to clear your system before a pregnancy begins, because the medicine is not recommended during pregnancy, breastfeeding, or while actively trying to conceive. If you are planning a family, talking to your prescriber or GP before making any changes to your treatment is the right first step — they can help you time the transition and discuss weight management in the interim. These are prescription-only medicines, and any decision to stop or pause treatment must be made with a clinician, not unilaterally.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The two-month minimum is not arbitrary. Semaglutide has a half-life of roughly one week, meaning it takes several weeks to fall to negligible levels in the body. NHS guidance on weight-management injections sets the two-month marker as the point at which clinicians consider the drug sufficiently cleared for conception to begin safely. That figure comes from the same NHS England guidance on weight-management injections that covers contraception and surgical planning for people on GLP-1 medicines.
In practice this means building the two months into your family-planning timeline well in advance, not as an afterthought once you have already decided to try. If you are unsure how long you have been on Wegovy or what dose you are currently taking, a quick check of your treatment records takes under a minute and gives you the date to count forward from. That simple habit matters here because the clock starts from your last dose, not from when you formally stop.
Your prescriber will also want to review your overall health before you stop. The NHS medicines page for semaglutide confirms that Wegovy is not recommended in pregnancy and that conception should be avoided during treatment.
Stopping Wegovy does not mean conception is safe immediately. Contraception should continue throughout treatment and for the full two months after the last injection. This is not a technicality. Semaglutide is still present and active in the body for several weeks after the final dose, and exposure during early pregnancy, before many people even know they are pregnant, is the risk the clearance window is designed to prevent.
One practical note for people on oral contraceptives: the NHS has not flagged the same absorption concern for semaglutide as it has for tirzepatide (where pill absorption can be reduced in the first weeks of treatment and after dose increases). Even so, any questions about which contraceptive method is most reliable alongside Wegovy are best put to a GP or prescriber directly, rather than worked out alone. If you are considering how long you can stay on Wegovy before a planned pregnancy, that page covers the evidence on treatment duration in detail. For anyone still deciding between treatment options, our treatment overview sets out what is licensed and available in the UK.
Weight regain after stopping a GLP-1 medicine is well documented. For many people, some weight returns within months of the last dose, because the appetite-regulating effect of semaglutide diminishes as it clears. This is not a treatment failure; it reflects the biology of how these medicines work, as described in the SURMOUNT and STEP trial programmes.
Going into a pregnancy at a higher BMI carries its own risks, including gestational diabetes, hypertension, and complications during delivery. So the two-month gap is an opportunity, not just a waiting period. A GP or dietitian can help build a dietary and activity plan that holds as much of the lost weight as possible during the transition. The detailed guide on being off Wegovy before pregnancy covers this planning in more depth, and our FAQs address some of the most common questions about pausing treatment. If you stopped Wegovy some time ago and are wondering whether the timeline still applies, the page on how long off Wegovy before pregnancy gives additional context on counting the clearance period correctly.
Stop taking it and contact your GP or midwife the same day. Current guidance does not describe confirmed teratogenic effects in humans, but the data from human pregnancies is limited, and animal studies have raised concerns at relevant doses. The conservative position, and the one supported by the medicine's UK licence, is that exposure in pregnancy should be avoided. If you are also wondering how long Wegovy takes to work, that page explains the timeline for the medicine's effects to build up and then diminish after stopping. Your GP can arrange appropriate early monitoring and advise on next steps.
If you were prescribed Wegovy through a regulated private service and need to pause or stop your treatment, contact our team and a prescriber will advise you. Our clinical approach means that stopping safely is handled with the same care as starting. Wegovy is a prescription-only medicine; any change in your treatment should involve a clinician, and if you want to understand how long you can take Wegovy as part of planning around a future pregnancy, a prescriber can help you work through the options, so the consultation page is the right place to start that conversation if you are not yet a patient.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.